Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

Cited by (438)

Items 401–438 of 438

1. Semaglutide and Tirzepatide in Cardiovascular and Cardiometabolic Risk Management: Evidence Maturity, Patient Selection, and Real-World Implementation
   Fayez Salahedin Alkhateeb · 2026 · SN Comprehensive Clinical Medicine
2. GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials
   Shi-ping Sun, Yan Fang, Li Liu, Yi Li, Han Min · 2026 · Frontiers in Medicine
3. Orforglipron versus oral semaglutide in type 2 diabetes, clinical implications of the ACHIEVE-3 trial
   Davide Bernasconi, Maria Elena Lunati, Paolo Fiorina · 2026 · Metabolism and Target Organ Damage
4. GLP-1 Receptor Agonists in Diabetic Lower Extremity Peripheral Artery Disease: From Mechanisms to Clinical Practice
   Jie Pan, Chengnan Guo, Qiuwei Huang, Yikai Zhang, Yimin Shen, Caiyun Guo · 2026 · British Journal of Hospital Medicine
5. Cardiovascular outcomes of oral incretin-based drugs in type 2 diabetes: a GRADE-assessed meta-analysis of 67,679 patients
   Muhammad Faizan Ali, Omer Farooq Mohammed, Amina Suhail, Faisal Naseer, Nimra Shafi, Muhammad Usman Arshad, Omar Shazly, Muneeb Shad Mohmand, Husnain Ahmad, Noof K. Binashikhbubkr et al. · 2026 · Frontiers in Cardiovascular Medicine
6. Semaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives
   Enrico Maggio, Sara Trivigno, Marco Valerio Mariani, Agostino Piro, Nicola Pierucci, Antonio Vernile, Sara Vinciullo, Massimiliano Palombi, Carmine Dario Vizza, Carlo Lavalle · 2026 · Journal of Personalized Medicine
7. GLP-1 receptor agonists—a potential therapy for chronic kidney disease?
   Jan Boeckhaus, John Andrew Sayer, Holly R. Mabillard · 2026 · Clinical Science
8. Global Landscape and Thematic Evolution of Selective GLP ‐1 Receptor Agonists and GLP ‐1–Based Multi‐Receptor Agonists in Type 2 Diabetes Mellitus: A Bibliometric Analysis
   Yanbing Wang, Zhanru Liu, Shifeng Wang, Cuiyan Lv, Hesham Rushdey El-Seedi, Shaden A M Khalifa, Haiyan Wang · 2026 · Endocrinology Diabetes & Metabolism
9. PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction
   Giuseppe Miceli, Maria Grazia Basso, M. Cuffaro, Antonino Marchese, Antonino Tuttolomondo · 2026 · Medicina
10. GLP-1 Receptor Agonists Beyond Metabolic Control: Cardiovascular Benefits, Renal Protection, Neurological Effects and Socioeconomic Implications of Widespread Use.
    Weronika Wrona, Anna Wojdas, Wiktoria Wdowiak, Małgorzata Dorożalska, Małgorzata Jurczyk, Aleksandra Glapa, Hanna Ludwisiak, Maja Cwalina, Julia Owsik, Weronika Ryś · 2026 · Quality in Sport
11. GLP-1 receptor agonists in cardiometabolic disease: a meta-analysis of 102,486 patients
    Zena Adel Alwaily, Obaid Ur Rahman, Aung Thet Swe, Aya Abouayana, Navdeep Singh Sodhi, Mei Jia Goh, Adeel Ahmed, Tharun Adithya Natesan, Shahzaib Shahzad, Om Harsh Merchant et al. · 2026 · Archives of Medical Science - Atherosclerotic Diseases
12. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)
    Matthew Aaron Cavender, Ania M. Jastreboff, ALICE Y.Y. CHENG, Melanie Jane Davies, Lucienne Donaldson, Lars‐Ole Gerlach, Silas Hinsch Gylvin, Jacob Bonde Jacobsen, Nikolaus Marx, Cynthia Karenina Osorto et al. · 2026 · American Heart Journal
13. Kidney Outcomes With GLP ‐1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real‐World Cohort Study
    Dvora Rywka Sehtman-Shachar, Alisa Fishkin, Gil Leibowitz, Ofri Mosenzon, Meir Schechter, Genya Aharon‐Hananel · 2026 · Diabetes Obesity and Metabolism
14. U.S. Trends in 10-Year Cardiovascular Risk Scores Over 2 Decades
    Yelena R. Drexler, Ofek Goldwasser, Connor McCarley, Danielle Land, Cayetano Naranjo, Vinodh Mechery, Shathiyah Kulandavelu, Tatjana Rundek, Eugene Yang, Tali Elfassy · 2026 · JACC Advances
15. Making Inflammation Measurable: hsCRP in Cardiovascular Risk Assessment – A Practical Framework for Canadian Care
    Fallon Dennis, Charles P.B. Higgins, Mina Madan, Christopher B. Fordyce, Robert Welsh, Jonathan G. Howlett, Shaun G. Goodman, Grace L. Chua, Anique Ducharme, Nadia Bouabdallaoui et al. · 2026 · CJC Open
16. Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat
    Hussein Zaitoon, Muhammad A. Abdul-Ghani, Ralph A. DeFronzo · 2026 · EClinicalMedicine
17. Therapie des Typ-2-Diabetes – Praxisempfehlung der DDG
    Baptist Gallwitz, Jens Aberle, Andreas L. Birkenfeld, Monika Kellerer, Harald H. Klein, Rüdiger Landgraf, Dirk Müller‐Wieland, Karsten Müssig, M. Nauck, Erhard G. Siegel et al. · 2026 · Diabetologie und Stoffwechsel
18. Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes
    Yu Mi Kang, Michael A Nauck · 2026 · The Lancet
19. Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis
    Nicholls, Stephen J, Pavo, Imre, Bhatt, Deepak L, Buse, John B, Del Prato, Stefano, Franco, Denise R, Kahn, Steven E, Lincoff, A Michael, Martins, Ricardo Fonseca, McGuire, Darren K et al. · 2026 · European Journal of Preventive Cardiology
20. Beyond glycemic control: cardiovascular and kidney benefits of GLP-1 receptor agonists and the dual GIP/GLP-1 receptor agonist tirzepatide: a narrative review
    Filip Kierzkowski, Wiktoria Skrzypek, Wiesław Bryl, Anna Paczkowska, Karolina Hoffmann · 2026 · Frontiers in Endocrinology
21. Type 2 diabetes and the cardio–renal–metabolic syndrome: The evolving roles of GLP-1 and dual GLP-1/GIP receptor agonists
    Clipper F Young, Namrita George, Alexander Olson, Isaacs Diana · 2026 · touchREVIEWS in Endocrinology
22. Mechanism-based therapeutic strategies in cardiovascular-kidney-metabolic syndrome: integrating biological pathways with evidence from clinical trials
    John Nzobokela, Simweene C. Choolwe, Sepiso Kenias Masenga · 2026 · Frontiers in Endocrinology
23. GLP-1-Based Therapies for Cardiovascular Risk Reduction in Kazakhstan: Evidence, Affordability, Equity and Implementation Considerations
    Kulzhan Berikkhanova, Isah Inuwa, Yessenkhan Sultan, Nurzhan Berikkhanov, Saule Rakhimova, Ainur R. Akilzhanova · 2026 · Journal of Clinical Medicine
24. GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications
    Rachelle Jang, Michelle Jang, Xinyuan Ruan, Caden Jin, Woo Kim · 2026 · European Journal of Clinical Pharmacology
25. Cardiovascular–kidney–metabolic syndrome: novel molecular mechanism and glucagon-like peptide-1-targeting therapy
    Fengzhao Liu, Zihan Xu, Wenru Wang, Junwei Gao, Changgeng FU, Peng Liu · 2026 · Frontiers in Cell and Developmental Biology
26. Parasympathetic dysfunction assessed by deep‐breathing CVR ‐R is associated with early discontinuation of oral semaglutide in type 2 diabetes: A multicenter retrospective study
    Kazuma Ogiso, Takahisa Deguchi, Shigeru Kawade, Aiko Arimura, Yoshihiko Nishio, Katsutaro Morino · 2026 · Journal of Diabetes Investigation
27. Precision medicine approaches in diabetic cardiomyopathy: from molecular mechanisms to personalized therapeutic strategies
    Vaibhavkumar Patel, Kinjal Patel, Bhakti Patel, Drashti Patel, Aarti Kushwaha · 2026 · Journal of Molecular and Cellular Cardiology
28. Use of SGLT2 Inhibitors, GLP ‐1 Receptor Agonists, and DPP ‐4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations
    Ying‐Hsuan Lin, Daniel Hsiang‐Te Tsai, Miyuki Hsing‐Chun Hsieh, Chia-Chun Lee, Chin‐Chung Tseng, Ming-Cheng Wang, Edward Chia‐Cheng Lai, Kuan‐Hung Liu · 2026 · Clinical Pharmacology & Therapeutics
29. Incretin and nutrient-sensing GPCR therapeutics in type 2 diabetes: What target–modality–formulation matching explains
    Yohan Seo, Joohan Woo · 2026 · Drug Discovery Today
30. Practical Challenges of Switching and Cross-Titration Between Incretin-Based Therapies in Type 2 Diabetes and Obesity: A Narrative Review
    Jana Makuc, Miodrag Janić · 2026 · Journal of Clinical Medicine
31. Cardiovascular Effects of GLP ‐1 Receptor Agonists Across Age Groups: An Updated Meta‐Analysis of Randomized Controlled Trials
    Ai Fujii, Masashi Hasebe, Kengo Furuichi, Daisuke Yabe, Satoshi Yoshiji · 2026 · Diabetes Obesity and Metabolism
32. Loss of Female Cardiovascular Protection in Diabetes: From Mechanisms to Intervention
    Jillian P. Gady, Shanjida Akter, Mark VandeWiele, Feng Dong · 2026 · Cells
33. Newer Diabetes Medications in Older Adults with or At Risk for Cardiovascular Disease
    Laura B. Bovee, Arthi Thirumalai · 2026 · Current Geriatrics Reports
34. Neue orale Adipositasmedikamente – Zukunft oder zweite Wahl?
    H. Hauner · 2026 · Die Innere Medizin
35. GLP-1 Receptor Agonists in Metabolic Dysfunction–Associated Steatotic Liver Disease and Cardiovascular Disease
    Sarah Rahni, Edward Lebovics, William H. Frishman, Wilbert S. Aronow · 2026 · Cardiology in Review
36. Cardiovascular and diabetes outcomes after metabolic bariatric surgery versus obesity management medications: nationwide overlap-weighted cohort study of 379 858 patients
    Andrew P. Gillikin, Emily P. Rabinovich, Abdelrahman Ali Nimeri, Ali Tavakkoli, Thomas H. Shin · 2026 · British journal of surgery
37. Association Between Weight Loss on Incretin‐Based Therapy and Cardiovascular Outcomes and Mortality: A Systematic Review and Meta‐Regression
    Marko Skelin, Bruna Perkov-Stipičin, Vlatka Bračić, Zvonimir Škugor, Ivan Krečak · 2026 · Diabetes Obesity and Metabolism
38. Direct cardiac or systemic? Reexamining the cardiovascular mechanisms of SGLT2 inhibitors and GLP-1 receptor agonists
    Amanda Osmanlli, Rebecca Conforto, John Roy, Jasmine Hardersen, Zhao Li · 2026 · Journal of Basic and Clinical Physiology and Pharmacology